Pharmacokinetic evaluation of thiacetazone

Pharmacotherapy

Volumn 16, Issue 5 I, 1996, Pages 735-741

  Peloquin, Charles A ^a,b   Nitta, Annette T ^a,c   Berning, Shaun E ^a   Iseman, Michael D ^a,c   James, Gordon T ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TB 1; THIOACETAZONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SCREENING; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MYCOBACTERIUM INTRACELLULARE AVIUM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RASH;

ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; DRUG ERUPTIONS; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; THIOACETAZONE;

EID: 0029742179     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bartman K, ed. Antituberculosis drugs. Handbook of experimental pharmacology, vol 84. New York: Springer-Verlag, 1988.
2. Kucers A, Bennett N McK, eds. The use of antibiotics, 4th ed. Philadelphia: JB Lippincott, 1988:1432-35.
3. Fox W, Stark AJ, Tall R, et al. A study of adverse reactions to high dosage intermittent thiacetazone. Tubercle 1974;55:29-40.
4. Ellard GA, Dickinson JM, Gammon PT, et al. Serum concentrations and antituberculosis activity of thiacetazone. Tubercle 1974;55:41-54.
5. Sen PK, Chatterjee JR, Roy, HS. Thiacetazone concentration in blood related to grouping of tubercular patients, its treatment, results, and toxicity. Indian J Med Res 1974;62:557-64.
6. Sen PK, Chatterjee JR, Saha JR. Thiacetazone and INH in tuberculosis. Synchronized peak concentration drug administration for greater action. J Indian Med Assoc 1973;61:306-8.
7. Jenner PJ, Ellard GA, Swai OB. A study of thiacetazone blood levels and urinary excretion in man, using high performance liquid chromatography. Lepr Rev 1984;55:121-9.
8. Heifets LB. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agent Chemother 1988;32:1131-6.
9. Heifets LB, Lindholm-Levy PJ, Flory M. Thiacetazone: in vitro activity against Mycobacterium avium and M. tuberculosis. Tubercle 1990;71:287-91.
10. Tsukamura M. Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by Mycobacterium avium complex. Am Rev Respir Dis 1988;137:144-8.
11. Peloquin CA. Controversies in the management of Mycobacterium avium complex (MAC) infection. Ann Pharmacother 1993;27:928-37.
12. O'Brien RJ. Pulmonary disease due to Mycobacterium avium complex. Semin Respir Med 1988;9:492-7.
13. Docktor WJ. Creatinine clearance. In: Mungall D, ed. Applied clinical pharmacokinetics. New York: Raven Press, 1983:349-66.
14. Jenner PJ. High performance liquid chromatographic determination of thiacetazone in body fluids. J Chromatogr 1983;276:463-70.
15. Jelliffe RW. Explicit determination of laboratory assay error patterns - a useful aid in therapeutic drug monitoring. American Society of Clinical Pathology check sample continuing education program. Drug Monit Toxicol 1989;10:1-6.
16. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;10:31-41.
18. Jelliffe RW, Schumitzky A, Van Guilder M. User manual for version 10.1 USC*PACK collection of PC programs. Los Angeles: Laboratory of Applied Pharmacokinetics, University of Southern California, 1994.
19. Kelly P, Buve A, Foster SD, McKenna M, Donnelly M, Sipatunyana G. Cutaneous reactions to thiacetazone in Zambia: implications for tuberculosis treatment strategies. Trans R Soc Trop Med Hyg 1994;88:113-15.
20. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991;337:627-30.